Skip to main content
NCBI home page
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Am J Psychiatry. 2016 Aug 13;174(2):163–171. doi: 10.1176/appi.ajp.2016.16020204

Altered expression of ARP2/3 complex signaling pathway genes in prefrontal layer 3 pyramidal cells in schizophrenia

Dibyadeep Datta 1,2, Dominique Arion 2, Kaitlyn M Roman 2, David W Volk 2, David A Lewis 1,2
PMCID: PMC5288270  NIHMSID: NIHMS796764  PMID: 27523502

Abstract

Objective

Lower dendritic spine density on layer 3 pyramidal cells in the dorsolateral prefrontal cortex (DLPFC) appears to contribute to cognitive dysfunction in schizophrenia, whereas psychosis is associated with excessive dopamine release in the striatum. These findings might be related via excitatory projections from the DLPFC to the ventral mesencephalon, the location of dopamine cells projecting to the striatum. Consistent with this hypothesis, deletion of the actin-related protein-2/3 (ARP2/3) complex, which regulates the actin cytoskeleton supporting dendritic spines, produced spine loss in cortical pyramidal cells and striatal hyperdopaminergia in mice. However, whether the ARP2/3 complex is altered in schizophrenia is unknown.

Method

In matched pairs of schizophrenia and comparison subjects, transcript levels of ARP2/3 complex signaling pathway were assessed in laser-microdissected DLPFC layer 3 and 5 pyramidal cells and layer 3 parvalbumin interneurons, and in total DLPFC gray matter.

Results

Transcript levels of ARP2/3 complex subunits, and of nucleation promotion factors that regulate the ARP2/3 complex, were significantly lower in DLPFC layer 3 and 5 pyramidal cells in schizophrenia. In contrast, these transcripts were unaltered, or only modestly changed, in parvalbumin interneurons and DLPFC gray matter.

Conclusions

Downregulation of the ARP2/3 complex signaling pathway, a common final pathway for multiple signaling cascades that regulate the actin cytoskeleton, would compromise the structural stability of spines, leading to their loss. In concert with findings from deletion of the ARP2/3 complex in mice, these findings support the idea that spine deficits in the DLPFC might contribute to subcortical hyperdopaminergia in schizophrenia.

Keywords: actin cytoskeleton, dendritic spines, glutamate, prefrontal cortex, pyramidal cells, schizophrenia

Introduction

Cognitive deficits constitute a core feature of schizophrenia(1), are persistent across the course of the illness(2) and are the best predictor of long-term functional outcome(3). At least some of these deficits arise during childhood and adolescence, prior to the onset of the psychosis associated with a clinical diagnosis of schizophrenia(4).

The impairments in certain cognitive processes, such as working memory, appear to reflect alterations in specific elements of dorsolateral prefrontal cortex (DLFPC) circuitry known to be critical for working memory in primates(5). For example, reciprocal excitatory connections among DLPFC layer 3 pyramidal cells are thought to mediate sustained neuronal activity during the maintenance phase of working memory in monkeys(6); in individuals with schizophrenia these neurons have fewer dendritic spines, the principal site of glutamatergic inputs(7). In contrast, the psychotic symptoms of schizophrenia are associated with excessive dopamine release in the associative striatum(8).

These two domains of schizophrenia pathology and pathophysiology have been hypothesized to be related via the excitatory projections from the DLPFC to the ventral mesencephalon, the location of the dopamine cells that project to the striatum(9). That is, the deficit in dendritic spines, and the resulting reduction in excitatory drive to DLPFC pyramidal cells, is thought to lead to the hyperdopaminergic state subcortically(10). Consistent with this hypothesis, conditional deletion in mice of the actin-related protein-2/3 (ARP2/3) complex, which acts as a common final pathway for multiple signaling cascades that regulate the actin cytoskeleton required for dendritic spine formation and maintenance(11, 12), produced a loss of dendritic spines in prefrontal cortical pyramidal cells and elevated striatal dopamine neurotransmission(13). These changes were accompanied by cognitive deficits and antipsychotic-responsive locomotor hyperactivity(13, 14). The idea that a spine deficit in PFC pyramidal neurons was the upstream cause of increased subcortical dopamine was supported by proof-of-concept evidence that viral re-expression of the ARP2/3 complex in frontal cortical pyramidal neurons lowered striatal dopamine levels and reduced locomotor hyperactivity(13).Together, these findings provide a mechanistic basis for the prior observation that diminished activity in the DLPFC predicted subcortical hyperdopaminergia in schizophrenia(15). However, it is not known if expression of the ARP2/3 complex in DLPFC pyramidal cells is deficient in schizophrenia.

Therefore, the goal of the present study was to examine the ARP2/3 complex signaling pathway (Figure 1A) in DLPFC deep layer 3 pyramidal cells where dendritic spine alterations are most pronounced in schizophrenia(16, 17). We used laser microdissection to capture individual pyramidal cells in DLPFC deep layer 3 from subjects with schizophrenia and matched unaffected comparison subjects and assessed gene expression in pools of neurons from each subject by microarray analysis. In order to assess the cell type-specificity of the findings, we analyzed microarray data from layer 5 pyramidal cells and layer 3 parvalbumin interneurons, and we measured expression levels of certain transcripts in total DLPFC gray matter using quantitative reverse-transcription polymerase chain reaction. In each analysis, we evaluated transcript levels for all subunits of the ARP2/3 complex and of nucleation-promotion factors that regulate the activity of the ARP2/3 complex (Figure 1A).

Figure 1. Schematic illustration of the ARP2/3 complex signaling pathway and contribution to spine deficits in schizophrenia.

Figure 1

Open in a new tab

Panel A depicts nucleation promotion factors (NPFs) that regulate the activity of ARP2/3 complex in a healthy state. NPFs include Neural Wiskott-Aldrich syndrome (N-WASP) protein encoded by WASL, WASP family Verprolin-homologous (WAVE) proteins, cytoplasmic FMR1 interacting protein I (CYFIP1) and cortactin that act downstream of Rho GTPases such as CDC42 and RAC. Activation of the ARP2/3 complex by multiple nucleation promotion factors results in actin nucleation and polymerization to generate F-actin branched filaments from existing F-actin monomers. Arrows indicate activation. Panel B illustrates the molecular cascades of ARP2/3 complex dysregulation in schizophrenia. The marked decrement in mRNA levels for CYFIP1, cortactin and N-WASP and ARP2/3 complex subunits in DLPFC layer 3 pyramidal cells converge to decrease F-actin nucleation and polymerization required for spinogenesis contributing to spine deficits.

Materials and Methods

Human subjects

Brain specimens (N=124) were obtained during routine autopsies conducted at the Allegheny County Office of the Medical Examiner (Pittsburgh, PA), after consent was obtained from the next-of-kin(18). Subject groups for the entire cohort (N=62 pairs; see Supplemental Table S1 for individual subject details), and for the subsets of pairs used in specific studies, did not differ in mean age, postmortem interval (PMI), RNA integrity number (RIN; Agilent Bioanalyzer, Santa Clara, CA), tissue storage time at −80°C (all t1220.45, all p>0.65) or race (X2=1.75; p=0.186) (Table 1). Brain pH was significantly different between subject groups for the entire cohort (t122=2.6, p=0.01), but the difference was quite small (0.1 pH unit) and of uncertain biological significance. All procedures were approved by the University of Pittsburgh’s Committee for the Oversight of Research and Clinical Trials Involving the Dead and Institutional Review Board for Biomedical Research.

Table 1.

Summary of subject characteristics.

Characteristic Microarray (Pyramidal Cells) Microarray (PV Cells) qPCR (Gray Matter)
Comparison
(N=36)		 Schizophrenia
(N=36)		 Comparison
(N=14)		 Schizophrenia
(N=14)		 Comparison
(N=62)		 Schizophrenia
(N=62)
N % N % N % N % N % N %
Male 27 75 27 75 10 71.4 10 71.4 47 75.8 47 75.8
Race
 White 30 83.3 24 66.7 12 85.7 10 71.4 52 83.9 46 74.2
 Black 6 16.7 12 33.3 2 14.3 4 28.6 10 16.1 16 25.8
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Age (years) 48.1 13.0 46.9 12.4 46.7 11.3 44.3 11.2 48.7 13.8 47.7 12.7
Postmortem Interval
(hours)		 17.6 6.1 18.0 8.8 17.1 6.6 17.7 8.4 18.8 5.5 19.2 8.5
RNA Integrity Number 8.3 0.6 8.2 0.6 7.8 0.5 7.8 0.5 8.2 0.6 8.1 0.6
Brain pH 6.7 0.2 6.6 0.4 6.7 0.2 6.4 0.2 6.7 0.2 6.6 0.3
Storage Time
(months)		 122.2 49.8 125.7 53.1 91.7 22.4 85.2 9.6 152.8 56.5 149.1 60.9
Open in a new tab

M, Male; F, Female; W, White; B, Black.

Values are mean ± SD.

For between group comparisons within each type of analysis, all t122<0.45 and all p>0.65 and race (X2= 1.75; p=0.186). Brain pH was significantly different between schizophrenia and healthy comparison subject groups in PV cells (t26=4.3, p<0.001) and gray matter (t122=2.6, p=0.01).

Laser Microdissection Procedure

As previously described(19, 20), cryostat sections (12 μm) containing DLPFC area 9 were thaw-mounted onto glass PEN membrane slides (Leica Microsystems, Bannockburn, Illinois) and stained for Nissl substance with thionin. Using a Leica laser microdissection system, DLPFC deep layer 3 and layer 5 were identified in portions of the section cut perpendicular to the pial surface. Nissl-stained pyramidal neurons, identified by their characteristic triangular shape and prominent apical dendrite, were individually dissected from each laminar location. Parvalbumin interneurons were identified by dual-labeling of NeuN-positive interneurons and Vicia villosa agglutinin (VVA) labeling of perineuronal nets in layers 3 and 4(21).

Microarray Analyses

For pyramidal cell microarray analyses(19, 21), 200 DLPFC pyramidal cells from deep layer 3 and from layer 5 were dissected individually and then pooled together by layer for each subject (N=36 pairs)(19). Array results were not readable for layer 5 samples from two schizophrenia subjects and thus two subject pairs were excluded. For parvalbumin interneuron microarray analyses, 360 parvalbumin interneurons were dissected from 14 of the 36 subject pairs(21). The cDNA from each sample was loaded on an Affymetrix GeneChip® HT HG-U133+ PM Array plate (Affymetrix, Santa Clara, CA) designed to assess transcript levels from the human genome.

We also used microarray analyses to evaluate ARP2/3 complex signaling pathway transcripts in DLPFC deep layer 3 pyramidal cells from monkeys with chronic exposure to olanzapine, haloperidol or placebo (Supplementary Methods).

Quantitative Polymerase Chain Reaction

For each subject in the full cohort (N=62 pairs), area 9 gray matter was collected and cDNA prepared as previously described(18) (Supplementary Methods). Based on their stable levels of expression across schizophrenia and comparison subjects, three reference genes (beta-actin, cyclophilin-A, and glyceraldehyde-3-phosphate dehydrogenase [GAPDH]) were used to normalize target mRNA levels. The difference in CT (dCT) for each target transcript was calculated by subtracting the geometric mean CT of the three reference genes from the CT of the target transcript. Since dCT represents the log2-transformed expression ratio of each target transcript to the reference genes, the relative level of the target transcript for each subject is reported as 2-dCT.

Data Analysis and Statistics

A comprehensive description of the statistical analyses used for the microarray data is provided in Arion et al. 2015(19). Briefly, Affymetrix CEL files were normalized and log2 transformed using RMA Express. After filtering to remove uninformative probe sets, the Random Intercept Model with Bayesian Information Criterion variable selection (RIM-BIC) was used to analyze the microarray data set. An adaptively weighted Fisher’s method was used to combine the differential expression information for each transcript and the Benjamini-Hochberg protocol was used to control the false discovery rate (<.05) for the meta-analyzed p-values.

In a separate analysis, the microarray signals for all probe sets targeting each ARP2/3 complex transcript were averaged within each sample and used in two analyses of covariance (ANCOVA) models. The paired ANCOVA used the level of each mRNA as the dependent variable, diagnostic group as the main effect, subject pair as a blocking factor, and PMI, storage time, brain pH and RIN as covariates. However, subject pairing may be considered an attempt to account for the parallel processing of tissue samples from a pair and to balance diagnostic groups for sex and age, and thus to not be a true statistical paired design. Consequently, we also used an unpaired ANCOVA that included age, sex, PMI, storage time, brain pH and RIN as covariates. These same two models were used to analyze the data from the qPCR analyses. Because both models gave the same results with regards to statistical significance, only the results from the unpaired model are presented below (see Supplementary Table S3 for the paired model results).

The influence of comorbid factors on ARP2/3 complex signaling pathway transcript expression was assessed by ANCOVA (Supplementary Methods).

For all ANCOVAs, reported statistics include only the covariates that were statistically significant. As a result, the reported degrees of freedom vary across analyses.

Results

Expression levels of ARP2/3 complex signaling pathway genes in DLPFC deep layer 3 pyramidal cells in schizophrenia

Using a false discovery rate of 5%, 7 of the 12 transcripts in the ARP2/3 complex signaling pathway were significantly downregulated in DLPFC deep layer 3 pyramidal cells from schizophrenia subjects and another 3 transcripts showed a trend (p<.09) towards downregulation (Table 2). As a number of transcripts were represented on the Affymetrix array by more than one probeset, the microarray signal for redundant probe sets was averaged within each sample. The resulting mRNA levels were compared between subject groups by ANCOVA as described in the following paragraphs.

Table 2.

Summary of ARP2/3 complex signaling pathway alterations in DLPFC deep layer 3 and layer 5 pyramidal cells in schizophrenia by microarray.

ARP2/3 Complex
Signaling Pathway
Transcripts		 Probesets % Change in Layer
3 Pyramidal Cells		 p-value % Change in Layer
5 Pyramidal Cells		 p-value
ACTR2 1554390_PM_s_at −11.38 0.006 −12.66 0.011
1558015_PM_s_at −10.41 0.006 −11.82 0.025
200729_PM_s_at −7.68 0.105 −8.39 0.147
ACTR3 200996_PM_at −19.50 0.001 −23.79 0.000
213101_PM_s_at −12.67 0.002 −14.32 0.014
213102_PM_at −13.12 0.001 −17.28 0.002
ARPC1A 200950_PM_at 3.67 0.478 2.66 0.701
ARPC1B 201954_PM_at −4.50 0.302 −2.29 0.539
ARPC2 207988_PM_s_at −17.63 0.002 −21.18 0.001
208679_PM_s_at −22.41 0.003 −25.41 0.011
213513_PM_x_at −3.85 0.131 −2.44 0.424
ARPC3 208736_PM_at −15.99 0.001 −16.88 0.005
ARPC4 211672_PM_s_at −11.70 0.003 −10.57 0.162
217817_PM_at −14.00 0.001 −16.57 0.001
217818_PM_s_at −7.83 0.009 −3.50 0.395
ARPC5 211963_PM_s_at −11.84 0.031 −22.40 0.008
1555797_PM_a_at −8.43 0.051 −6.43 0.190
CTTN 201059_PM_at −11.33 0.066 −14.09 0.041
214073_PM_at −21.23 0.109 −38.45 0.008
WASL 224813_PM_at −10.38 0.028 −13.11 0.051
230340_PM_s_at −12.30 0.044 −22.25 0.004
205809_PM_s_at −7.55 0.225 −18.36 0.021
CYFIP1 208923_PM_at −14.34 0.080 −17.77 0.006
WASF1 204165_PM_at 4.59 0.076 2.54 0.270
Open in a new tab

The ARP2/3 complex, which stimulates de novo actin nucleation and polymerization to generate F-actin branched filament networks that modulate spine morphogenesis, is composed of seven subunits(11). The ACTR2 and ACTR3 transcripts encode the ARP2 and ARP3 subunits which function as the ATP-binding component of the complex. In layer 3 pyramidal cells, mean transcript levels were significantly lower for both ACTR2 (−10.9%; F1,70=11.4, p=0.001) and ACTR3 (−15.2%; F1,70=16.9, p<0.001) in the schizophrenia subjects (Figure 2). The five ARPC subunits of the ARP2/3 complex are critical for actin binding and nucleation. In subjects with schizophrenia, mean transcript levels were lower for ARPC2 (−14.9%; F1,69=12.0, p=0.001), ARPC3 (−15.9%; F1,70=9.3, p=0.003), ARPC4 (−11.2%; F1,69=17.4, p<0.001) and ARPC5 (−10.2%; F1,68=6.8, p=0.011). The mean levels of the two human isoforms of ARPC1 (ARPC1A and ARPC1B) did not differ between subject groups (all F1,35≤1.1, all p≥0.30).

Figure 2. Microarray analyses of ARP2/3 complex signaling pathway mRNA levels in DLPFC deep layer 3 pyramidal cells in matched pairs of schizophrenia and healthy comparison subjects.

Figure 2

Open in a new tab

Log2-transformed microarray signals of (A) ACTR2, (B) ACTR3, (C) ARPC1A, (D) ARPC1B, (E) ARPC2, (F) ARPC3, (G) ARPC4, (H) ARPC5, (I) CTTN, (J) WASL, (K) CYFIP1, and (L) WASF1 mRNAs in DLPFC deep layer 3 pyramidal cells, for schizophrenia subjects relative to matched unaffected comparison subjects plotted for each pair (open circle). The data points below the diagonal unity line indicate lower mRNA signal in the schizophrenia subject relative to the matched unaffected comparison subject and vice versa.

The ARP2/3 complex is regulated by nucleation promotion factors including cortactin (CTTN); Neural Wiskott-Aldrich syndrome (N-WASP) proteins; and WASP family Verprolin-homologous (WAVE) proteins, such as WAVE1, which is modulated by cytoplasmic FMR1 interacting protein 1 (CYFIP1)(11, 22). In layer 3 pyramidal cells, mean CTTN transcript levels were lower in schizophrenia subjects, although this difference did not quite achieve statistical significance (−16.4%; F1,70=3.9, p=0.053). Mean transcript levels for WASL, which encodes N-WASP, were lower (−10.1%; F1,69=7.69, p=0.007) in schizophrenia. For the WAVE complex, mean CYFIP1 transcript levels were lower (−14.3%; F1,68=4.7, p=0.033) in schizophrenia, whereas mean transcript levels for WAVE1 (encoded by WASF1) were unaltered (4.6%; F1,70=2.3, p=0.134).

Effects of comorbid factors on ARP2/3 complex signaling pathway transcripts

Levels of ARP2/3 complex signaling pathway mRNAs that differed between subject groups did not differ among the schizophrenia subjects as a function of diagnosis of schizoaffective disorder; history of substance dependence or abuse; use of nicotine, antipsychotics, antidepressants, or benzodiazepines and/or sodium valproate at the time of death; or death by suicide (all F1,33≤3.4, all p≥0.076) (Supplemental Figure 1), with the exception that schizophrenia subjects with a history of substance dependence or abuse had significantly lower ARPC4 (F1,34≤16.74, p=0.001) and ARPC5 (F1,33≤5.96, p=0.020) mRNA levels relative to those without such a history.

Effects of antipsychotic-exposure on ARP2/3 transcripts in monkeys

Transcript levels for ARP2/3 complex signaling pathway in DLPFC layer 3 pyramidal cells did not differ (all F2,10≤3.3, all p≥0.08) among monkeys chronically exposed to olanzapine, haloperidol or placebo (Supplemental Figure S2).

Cellular specificity of altered expression ARP2/3 complex signaling pathway transcripts in schizophrenia

To determine whether these transcript alterations in the ARP2/3 complex signaling pathway were also present in other cell types, we conducted similar microarray analyses in DLPFC layer 5 pyramidal cells. Using a false discovery rate of 5%, each probe set in the ARP2/3 complex signaling pathway showed the same pattern of downregulation in both layer 5 and layer 3 pyramidal cells in schizophrenia; probe sets for two transcripts (CTTN and CYFIP1) that were only at trend level of significance in layer 3 were clearly significantly lower in layer 5 pyramidal cells (Table 2). Consistent with these findings, ANCOVA analyses revealed lower mean mRNA levels for the ATP-binding component of the complex (ACTR2, ACTR3) and for the subunits that mediate actin binding and nucleation (ARPC2, ARPC3, ARPC4, ARPC5) (Figure 3). In addition, mean mRNA levels of the nucleation promotion factors (CTTN, WASL, and CYFIP1) were also lower (Figure 3).

Figure 3. Microarray analyses of ARP2/3 complex signaling pathway mRNA levels in DLPFC layer 5 pyramidal cells in matched pairs of schizophrenia and healthy comparison subjects.

Figure 3

Open in a new tab

Log2-transformed microarray signals of (A) ACTR2, (B) ACTR3, (C) ARPC1A, (D) ARPC1B, (E) ARPC2, (F) ARPC3, (G) ARPC4, (H) ARPC5, (I) CTTN, (J) WASL, (K) CYFIP1, and (L) WASF1 mRNAs in DLPFC layer 5 pyramidal cells, for schizophrenia subjects relative to matched unaffected comparison subjects plotted for each pair (open circle). The data points below the diagonal unity line indicate lower mRNA signal in the schizophrenia subject relative to the matched unaffected comparison subject and vice versa.

We also evaluated expression of transcripts in parvalbumin interneurons in a subset of subject pairs using data from an existing microarray dataset(21). With the exception of ARPC3 mRNA, which was significantly lower in PV interneurons (−51.5%; F1,26=7.4, p=0.012), mean mRNA levels of ARP2/3 complex signaling pathway transcripts in layer 3 PV neurons did not differ between subject groups (all F1,26≤2.9, all p≥0.10). These findings do not appear to be false negatives due to a smaller sample size because in these same 14 subject pairs multiple transcripts were significantly downregulated in layer 3 pyramidal cells in schizophrenia: ACTR2 (−12.7%; p=0.04), ACTR3 (−20.0%; p=0.002), ARPC2 (−21.3%; p=0.003), ARPC4 (−13.8%; p=0.009), WASL (−14.5%; p=0.019); levels of two other transcripts were also lower, but did not quite achieve statistical significance: ARPC3 (−18.2%; p=0.073) and CTTN (−24.6%; p=0.062). These findings suggest that within the same cortical layer, most alterations in the ARP2/3 complex signaling pathway are specific to, or at least enriched in, pyramidal cells relative to parvalbumin interneurons. However, caution is warranted in interpreting these findings given the technical caveat that the most severely affected parvalbumin interneurons might not have been identifiable for capture by laser microdissection(21).

ARP2/3 complex signaling pathway transcripts in DLPFC gray matter in schizophrenia

To further test the cell type-specificity of alterations in the ARP2/3 complex signaling pathway, we analyzed transcript levels in total DLPFC gray matter by qPCR (Supplemental Table S3) in the same 36 pairs of subjects used for the pyramidal cell profiling. In contrast to the findings in pyramidal cells, mean mRNA levels in the schizophrenia subjects were higher for ARPC3 (3.8%; F1,69=3.2, p=0.034), CTTN (5.9%; F1,67=7.6, p=0.007), and WASL (3.4%; F1,70=6.5, p=0.013). None of the other transcripts significantly differed between subject groups, with the exception of mRNA levels for ARPC5 which were significantly lower (−6.0%; F1,68=5.4, p=0.023), but this decrement was smaller than in pyramidal cells.

In order to control for possible false-negative findings due to sample size, the transcripts in the ARP2/3 complex signaling pathway were evaluated in DLPFC gray matter in a larger subject cohort (N=62 pairs). Of the 9 transcripts that were significantly lower in layer 3 and/or 5 pyramidal neurons in subjects with schizophrenia, 3 were increased in expression, 3 were not different and 3 were decreased, but the deficits were much smaller than in pyramidal cells (Supplemental Table S3).

Discussion

Our results identify lower mRNA levels of multiple subunits of the ARP2/3 complex, and of nucleation promotion factors that regulate the activity of the ARP2/3 complex, in DLPFC deep layer 3 and 5 pyramidal cells in schizophrenia (Figure 1B). These alterations appear to reflect the disease process of schizophrenia as they were not attributable to chronic treatment with antipsychotic medications, other factors frequently comorbid with schizophrenia or potential confounds. In contrast, expression levels of ARP2/3 complex signaling pathway transcripts were up-regulated, not altered, or only modestly lower in DLPFC parvalbumin interneurons and DLPFC gray matter. Furthermore, the expression deficits in ARP2/3 complex signaling pathways in pyramidal cells do not appear to reflect non-specific factors as multiple other transcripts are upregulated in these neurons(19, 23). Because the ARP2/3 complex signaling pathway is a critical determinant of F-actin nucleation and polymerization, dysregulation of the ARP2/3 complex signaling pathway in schizophrenia might contribute to actin cytoskeleton impairments and spine deficits in DLPFC pyramidal cells.

Predicted consequences of downregulated ARP2/3 complex signaling pathway in DLPFC pyramidal cells

In DLPFC pyramidal cells from schizophrenia subjects, the downregulation in mRNA levels for multiple ARP2/3 complex transcripts (e.g., ACTR2, ARPC2, ARPC3) would be predicted to contribute to spine deficits by suppressing de novo actin polymerization that generates the branched actin filament networks required for spine formation (Figure 1B)(24–26). In addition, high concentrations of the ARP2/3 complex are found in the spine head, where it is localized proximal to F-actin filaments(27). Therefore, reduced gene expression of ARP2/3 complex subunits would likely impair the actin nucleation and crosslinking of F-actin filaments that are critical for the activity-dependent structural plasticity of spines, contributing to decreased spine stability and ultimately spine loss.

The ARP2/3 complex also acts as a molecular hub downstream of several signaling pathways that promote the structural stabilization of F-actin filaments necessary for spine maintenance(28–31). For example, nucleation promotion factors are required to activate the intrinsically inactive ARP2/3 complex; specifically, the nucleation promotion factors N-WASP, cortactin and CYFIP1 bring the ARP2/3 complex and F-actin monomers together to initiate the synthesis of new F-actin filaments(32). Therefore, the downregulation of these nucleation promotion factors in schizophrenia might further diminish ARP2/3 complex activity in the following ways (Figure 1B).

First, activation of ARP2/3 complex by N-WASP favors branch nucleation which allows stabilization of newly synthesized F-actin filaments(33, 34); thus, lower levels of both N-WASP and the ARP2/3 complex in schizophrenia would likely result in reduced nucleation of spine precursors such as lamellipodia and filopodia. Indeed, knockdown of endogenous N-WASP by RNA interference decreased dendritic spine number in hippocampal pyramidal neurons(34).

Second, CYFIP1 acts through the WAVE regulatory complex and cortactin to regulate the actin-nucleating activity of the ARP2/3 complex(11, 22, 35); thus lower levels of CYFIP1, cortactin and ARP2/3 complex subunits would further impair F-actin filament turnover and actin cytoskeleton dynamics necessary for formation of dendritic spines.

Third, CYFIP1 inhibits dendritic protein translation in an activity-dependent fashion and promotes actin cytoskeleton remodeling(29) by acting downstream of brain-derived neurotrophic factor (BDNF) and its postsynaptic partner TrkB, which are crucial for spine enlargement and stabilization(36). Thus, the lower levels of both BDNF and TrkB in the DLPFC of subjects with schizophrenia(37, 38) would likely further exacerbate the negative impact of impaired ARP2/3 complex signaling on spine number in DLPFC pyramidal cells.

Laminar-specificity of spine pathology in DLPFC pyramidal cells in schizophrenia

Previous postmortem studies have revealed lower basilar dendritic spine density on deep layer 3, but not on layer 5 or 6 pyramidal neurons, from the same subjects with schizophrenia(16, 17). Given this apparent laminar specificity of spine deficits, we expected that alterations in the ARP2/3 complex signaling pathway would be more marked in deep layer 3 than layer 5 pyramidal cells. However, the presence of ARP2/3 complex signaling pathway alterations in pyramidal cells in both layers suggests that these deficits 1) are not a secondary consequence of a reduced number of pyramidal cell dendritic spines, and 2) might be a necessary but not a sufficient cause of reduced spine density.

The prominence of spine deficits in deep layer 3 pyramidal cells might be due to other factors upstream of the ARP2/3 complex, such as disturbances in certain components of the Rho-family GTPase cell division cycle 42 (CDC42) signaling pathway(23, 39) for the following reasons. First, some of the components of this pathway, such as CDC42 effector proteins (CDC42EPs), are preferentially expressed in layers 2-3 of the DLPFC(40) and the CDC42-CDC42EP pathway is dysregulated in DLPFC layer 3 pyramidal cells in schizophrenia(23, 39). Second, another CDC42 signaling pathway (CDC42-p21-activated serine/threonine protein kinases (PAK)-LIM domain-containing serine/threonine protein kinases (LIMK) signaling pathway) is also altered in DLPFC layer 3 pyramidal cells; these alterations could destabilize actin dynamics by reducing F-actin turnover through cofilin, a family of actin depolymerizing proteins(23). Third, in addition to disrupting the spine cytoskeleton in their own right, these impairments in CDC42 signaling could magnify the impact of the alterations in the ARP2/3 complex signaling pathway. For example, the intrinsically auto-inhibited N-WASP is directly activated by CDC42(41, 42); thus, deficits in CDC42 signaling could exacerbate the consequences of deficits in the N-WASP-ARP2/3 complex cascade. In summary, the prominence of spine deficits in DLPFC deep layer 3 pyramidal cells in schizophrenia might reflect the convergent effects of alterations in several different signaling pathways, each of which could destabilize the actin cytoskeleton.

Do actin cytoskeleton impairments reflect genetic liability for schizophrenia?

The altered expression of genes in the CDC42 and ARP2/3 signaling pathways might be related to genetic risk factors for schizophrenia. For example, the interaction of single nucleotide polymorphisms in CYFIP1, ARP2 and ARP3 were reported to be associated with increased risk for schizophrenia(43). GWAS studies in schizophrenia have revealed enrichment of risk variants in genes whose products are involved in the activity-regulated cytoskeleton-associated scaffold protein (ARC), postsynaptic density (PSD) protein complex and complement component 4 (C4) genes, which are heavily localized to dendritic spines and neuronal synapses(44–47). Aberrant expression of these gene products during postnatal development might exacerbate spine pruning and synapse loss in subjects with schizophrenia. In addition, de novo mutations in schizophrenia are over-represented among loci encoding cytoskeleton-associated proteins that regulate actin(48). These genetic findings are consistent with the idea that abnormalities intrinsic to DLPFC deep layer 3 pyramidal cells represent an “upstream” component in the disease process of schizophrenia(49, 50). That is, variants or mutations in genes that regulate the actin cytoskeleton, in concert with altered expression of cell type-specific gene products, might be the pathogenic substrate for spine deficits in schizophrenia.

Implications for the disease process of schizophrenia

The disease process of schizophrenia has been proposed to involve pathology in the DLPFC which contributes to the pathophysiology of psychosis(9). This hypothesis is supported from a temporal perspective by findings that cognitive deficits, including those that depend on DLPFC circuitry, emerge and progress years before the onset of psychosis (51, 52). In addition, activation of the DLPFC during cognitive tasks is inversely related to measures of striatal dopaminergic function in subjects with schizophrenia(15). Evidence for causality in this association was recently provided by findings that deletion of the ARP2/3 complex in mice, resulting in cortical spine deficits, also lead to a subcortical hyperdopaminergia that improves with antipsychotic medications and is reversible with restoration of prefrontal ARP2/3 expression(13). The findings of the present study demonstrate that this mechanism is plausible in schizophrenia by showing that the ARP2/3 complex signaling pathway is altered in DLPFC pyramidal cells. The resulting loss of dendritic spines on layer 3 pyramidal cells in the DLPFC could represent an upstream pathology that eventually gives rise to excessive dopamine function in the associative striatum and the appearance of psychosis(10).

Supplementary Material

Supplement 1
Supplement 2
Supplement 3

Acknowledgements

The authors gratefully acknowledge Mary Brady, BS for technical assistance. David A. Lewis currently receives investigator-initiated research support from Pfizer and in 2013 to 2015 served as a consultant in the areas of target identification and validation and new compound development to Autifony, Bristol-Myers Squibb, Concert Pharmaceuticals, and Sunovion.

Grant Support

Supported by National Institutes of Health Grants MH103204 (Dr. Lewis), MH043784 (Dr. Lewis) and MH100066 (Dr. Volk).

Footnotes

Previous Presentations: Presented in part at the 3rd annual meeting of the Molecular Psychiatry Association, San Francisco, October 30th-November 1st, 2015.

Disclosures

All other authors report no financial relationships with commercial interests.

Reference List

  • 1.Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol. 2000;14:1–21. [PubMed] [Google Scholar]
  • 2.Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M. Behavioral and intellectual markers for schizophrenia in apparently healthy maleadolescents. Am J Psychiatry. 1999;156:1328–1335. doi: 10.1176/ajp.156.9.1328. [DOI] [PubMed] [Google Scholar]
  • 3.Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321–330. doi: 10.1176/ajp.153.3.321. [DOI] [PubMed] [Google Scholar]
  • 4.Lesh TA, Niendam TA, Minzenberg MJ, Carter CS. Cognitive control deficits in schizophrenia: mechanisms and meaning. Neuropsychopharmacology. 2011;36:316–338. doi: 10.1038/npp.2010.156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Arnsten AF, Wang MJ, Paspalas CD. Neuromodulation of thought: flexibilities and vulnerabilities in prefrontal cortical network synapses. Neuron. 2012;76:223–239. doi: 10.1016/j.neuron.2012.08.038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Goldman-Rakic PS. Cellular basis of working memory. Neuron. 1995;14:477–485. doi: 10.1016/0896-6273(95)90304-6. [DOI] [PubMed] [Google Scholar]
  • 7.Glausier JR, Lewis DA. Dendritic spine pathology in schizophrenia. Neuroscience. 2013;251:90–107. doi: 10.1016/j.neuroscience.2012.04.044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, Kapur S. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012;69:776–786. doi: 10.1001/archgenpsychiatry.2012.169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987;44:660–669. doi: 10.1001/archpsyc.1987.01800190080012. [DOI] [PubMed] [Google Scholar]
  • 10.Lewis DA, Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat Med. 2006;12:1016–1022. doi: 10.1038/nm1478. [DOI] [PubMed] [Google Scholar]
  • 11.Goley ED, Welch MD. The ARP2/3 complex: an actin nucleator comes of age. Nat Rev Mol Cell Biol. 2006;7:713–726. doi: 10.1038/nrm2026. [DOI] [PubMed] [Google Scholar]
  • 12.Hotulainen P, Hoogenraad CC. Actin in dendritic spines: connecting dynamics to function. J Cell Biol. 2010;189:619–629. doi: 10.1083/jcb.201003008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Kim IH, Rossi MA, Aryal DK, Racz B, Kim N, Uezu A, Wang F, Wetsel WC, Weinberg RJ, Yin H, Soderling SH. Spine pruning drives antipsychotic-sensitive locomotion via circuit control of striatal dopamine. Nat Neurosci. 2015;18:883–891. doi: 10.1038/nn.4015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Kim IH, Racz B, Wang H, Burianek L, Weinberg R, Yasuda R, Wetsel WC, Soderling SH. Disruption of Arp2/3 results in asymmetric structural plasticity of dendritic spines and progressive synaptic and behavioral abnormalities. J Neurosci. 2013;33:6081–6092. doi: 10.1523/JNEUROSCI.0035-13.2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, Berman KF. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci. 2002;5:267–271. doi: 10.1038/nn804. [DOI] [PubMed] [Google Scholar]
  • 16.Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry. 2000;57:65–73. doi: 10.1001/archpsyc.57.1.65. [DOI] [PubMed] [Google Scholar]
  • 17.Kolluri N, Sun Z, Sampson AR, Lewis DA. Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. Am J Psychiatry. 2005;162:1200–1202. doi: 10.1176/appi.ajp.162.6.1200. [DOI] [PubMed] [Google Scholar]
  • 18.Volk DW, Chitrapu A, Edelson JR, Roman KM, Moroco AE, Lewis DA. Molecular Mechanisms and Timing of Cortical Immune Activation in Schizophrenia. Am J Psychiatry. 2015;172:1112–1121. doi: 10.1176/appi.ajp.2015.15010019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Arion D, Corradi JP, Tang S, Datta D, Boothe F, He A, Cacace AM, Zaczek R, Albright CF, Tseng G, Lewis DA. Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder. Mol Psychiatry. 2015;20:1397–1405. doi: 10.1038/mp.2014.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Datta D, Arion D, Lewis DA. Developmental Expression Patterns of GABAA Receptor Subunits in Layer 3 and 5 Pyramidal Cells of Monkey Prefrontal Cortex. Cereb Cortex. 2015;25:2295–2305. doi: 10.1093/cercor/bhu040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Georgiev D, Arion D, Enwright JF, Kikuchi M, Minabe Y, Corradi JP, Lewis DA, Hashimoto T. Lower gene expression for KCNS3 potassium channel subunit in parvalbumin-containing neurons in the prefrontal cortex in schizophrenia. Am J Psychiatry. 2014;171:62–71. doi: 10.1176/appi.ajp.2013.13040468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Chen B, Brinkmann K, Chen Z, Pak CW, Liao Y, Shi S, Henry L, Grishin NV, Bogdan S, Rosen MK. The WAVE regulatory complex links diverse receptors to the actin cytoskeleton. Cell. 2014;156:195–207. doi: 10.1016/j.cell.2013.11.048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Datta D, Arion D, Corradi JP, Lewis DA. Altered expression of CDC42 signaling pathway components in cortical layer 3 pyramidal cells in schizophrenia. Biol Psychiatry. 2015;78:775–785. doi: 10.1016/j.biopsych.2015.03.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Blanchoin L, Amann KJ, Higgs HN, Marchand JB, Kaiser DA, Pollard TD. Direct observation of dendritic actin filament networks nucleated by Arp2/3 complex and WASP/Scar proteins. Nature. 2000;404:1007–1011. doi: 10.1038/35010008. [DOI] [PubMed] [Google Scholar]
  • 25.Korobova F, Svitkina T. Arp2/3 complex is important for filopodia formation, growth cone motility, and neuritogenesis in neuronal cells. Mol Biol Cell. 2008;19:1561–1574. doi: 10.1091/mbc.E07-09-0964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Rouiller I, Xu XP, Amann KJ, Egile C, Nickell S, Nicastro D, Li R, Pollard TD, Volkmann N, Hanein D. The structural basis of actin filament branching by the Arp2/3 complex. J Cell Biol. 2008;180:887–895. doi: 10.1083/jcb.200709092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Racz B, Weinberg RJ. Organization of the Arp2/3 complex in hippocampal spines. J Neurosci. 2008;28:5654–5659. doi: 10.1523/JNEUROSCI.0756-08.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Clement JP, Aceti M, Creson TK, Ozkan ED, Shi Y, Reish NJ, Almonte AG, Miller BH, Wiltgen BJ, Miller CA, Xu X, Rumbaugh G. Pathogenic SYNGAP1 mutations impair cognitive development by disrupting maturation of dendritic spine synapses. Cell. 2012;151:709–723. doi: 10.1016/j.cell.2012.08.045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.De Rubeis S, Pasciuto E, Li KW, Fernandez E, Di Marino D, Buzzi A, Ostroff LE, Klann E, Zwartkruis FJ, Komiyama NH, Grant SG, Poujol C, Choquet D, Achsel T, Posthuma D, Smit AB, Bagni C. CYFIP1 coordinates mRNA translation and cytoskeleton remodeling to ensure proper dendritic spine formation. Neuron. 2013;79:1169–1182. doi: 10.1016/j.neuron.2013.06.039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Hayashi-Takagi A, Takaki M, Graziane N, Seshadri S, Murdoch H, Dunlop AJ, Makino Y, Seshadri AJ, Ishizuka K, Srivastava DP, Xie Z, Baraban JM, Houslay MD, Tomoda T, Brandon NJ, Kamiya A, Yan Z, Penzes P, Sawa A. Disrupted-in-Schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1. Nat Neurosci. 2010;13:327–332. doi: 10.1038/nn.2487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Penzes P, Beeser A, Chernoff J, Schiller MR, Eipper BA, Mains RE, Huganir RL. Rapid induction of dendritic spine morphogenesis by trans-synaptic ephrinB-EphB receptor activation of the Rho-GEF kalirin. Neuron. 2003;37:263–274. doi: 10.1016/s0896-6273(02)01168-6. [DOI] [PubMed] [Google Scholar]
  • 32.Pollard TD. Regulation of actin filament assembly by Arp2/3 complex and formins. Annu Rev Biophys Biomol Struct. 2007;36:451–477. doi: 10.1146/annurev.biophys.35.040405.101936. [DOI] [PubMed] [Google Scholar]
  • 33.Miki H, Sasaki T, Takai Y, Takenawa T. Induction of filopodium formation by a WASP-related actin-depolymerizing protein N-WASP. Nature. 1998;391:93–96. doi: 10.1038/34208. [DOI] [PubMed] [Google Scholar]
  • 34.Wegner AM, Nebhan CA, Hu L, Majumdar D, Meier KM, Weaver AM, Webb DJ. N-wasp and the arp2/3 complex are critical regulators of actin in the development of dendritic spines and synapses. J Biol Chem. 2008;283:15912–15920. doi: 10.1074/jbc.M801555200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Chia PH, Chen B, Li P, Rosen MK, Shen K. Local F-actin network links synapse formation and axon branching. Cell. 2014;156:208–220. doi: 10.1016/j.cell.2013.12.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Rex CS, Lin CY, Kramar EA, Chen LY, Gall CM, Lynch G. Brain-derived neurotrophic factor promotes long-term potentiation-related cytoskeletal changes in adult hippocampus. J Neurosci. 2007;27:3017–3029. doi: 10.1523/JNEUROSCI.4037-06.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Hashimoto T, Bergen SE, Nguyen QL, Xu B, Monteggia LM, Pierri JN, Sun Z, Sampson AR, Lewis DA. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci. 2005;25:372–383. doi: 10.1523/JNEUROSCI.4035-04.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry. 2003;8:592–610. doi: 10.1038/sj.mp.4001308. [DOI] [PubMed] [Google Scholar]
  • 39.Ide M, Lewis DA. Altered cortical CDC42 signaling pathways in schizophrenia: implications for dendritic spine deficits. Biol Psychiatry. 2010;68:25–32. doi: 10.1016/j.biopsych.2010.02.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Arion D, Unger T, Lewis DA, Mirnics K. Molecular markers distinguishing supragranular and infragranular layers in the human prefrontal cortex. Eur J Neurosci. 2007;25:1843–1854. doi: 10.1111/j.1460-9568.2007.05396.x. [DOI] [PubMed] [Google Scholar]
  • 41.Abdul-Manan N, Aghazadeh B, Liu GA, Majumdar A, Ouerfelli O, Siminovitch KA, Rosen MK. Structure of Cdc42 in complex with the GTPase-binding domain of the 'Wiskott-Aldrich syndrome' protein. Nature. 1999;399:379–383. doi: 10.1038/20726. [DOI] [PubMed] [Google Scholar]
  • 42.Rohatgi R, Ma L, Miki H, Lopez M, Kirchhausen T, Takenawa T, Kirschner MW. The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly. Cell. 1999;97:221–231. doi: 10.1016/s0092-8674(00)80732-1. [DOI] [PubMed] [Google Scholar]
  • 43.Yoon KJ, Nguyen HN, Ursini G, Zhang F, Kim NS, Wen Z, Makri G, Nauen D, Shin JH, Park Y, Chung R, Pekle E, Zhang C, Towe M, Hussaini SM, Lee Y, Rujescu D, St Clair D, Kleinman JE, Hyde TM, Krauss G, Christian KM, Rapoport JL, Weinberger DR, Song H, Ming GL. Modeling a genetic risk for schizophrenia in iPSCs and mice reveals neural stem cell deficits associated with adherens junctions and polarity. Cell Stem Cell. 2014;15:79–91. doi: 10.1016/j.stem.2014.05.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Kirov G, Pocklington AJ, Holmans P, Ivanov D, Ikeda M, Ruderfer D, Moran J, Chambert K, Toncheva D, Georgieva L, Grozeva D, Fjodorova M, Wollerton R, Rees E, Nikolov I, van de Lagemaat LN, Bayes A, Fernandez E, Olason PI, Bottcher Y, Komiyama NH, Collins MO, Choudhary J, Stefansson K, Stefansson H, Grant SG, Purcell S, Sklar P, O'Donovan MC, Owen MJ. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry. 2012;17:142–153. doi: 10.1038/mp.2011.154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, Roussos P, O'Dushlaine C, Chambert K, Bergen SE, Kahler A, Duncan L, Stahl E, Genovese G, Fernandez E, Collins MO, Komiyama NH, Choudhary JS, Magnusson PK, Banks E, Shakir K, Garimella K, Fennell T, DePristo M, Grant SG, Haggarty SJ, Gabriel S, Scolnick EM, Lander ES, Hultman CM, Sullivan PF, McCarroll SA, Sklar P. A polygenic burden of rare disruptive mutations in schizophrenia. Nature. 2014;506:185–190. doi: 10.1038/nature12975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Schizophrenia Working Group of the Psychiatric Genomics C Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–427. doi: 10.1038/nature13595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Sekar A, Bialas AR, Davis A, Hammond TR, Kamitaki N, Tooley K, Presumey J, Baum M, Genovese G, Rose SA, Handsaker RE, Schizophrenia Working Group of the Psychiatric Genomics C. Daly MJ, Carroll MC, Stevens B, McCarroll SA. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530:177–183. doi: 10.1038/nature16549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P, Georgieva L, Rees E, Palta P, Ruderfer DM, Carrera N, Humphreys I, Johnson JS, Roussos P, Barker DD, Banks E, Milanova V, Grant SG, Hannon E, Rose SA, Chambert K, Mahajan M, Scolnick EM, Moran JL, Kirov G, Palotie A, McCarroll SA, Holmans P, Sklar P, Owen MJ, Purcell SM, O'Donovan MC. De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014;506:179–184. doi: 10.1038/nature12929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Cho RY, Lewis DA. Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia. Biol Psychiatry. 2015;77:1031–1040. doi: 10.1016/j.biopsych.2015.03.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Lewis DA, Curley AA, Glausier JR, Volk DW. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012;35:57–67. doi: 10.1016/j.tins.2011.10.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Gur RC, Calkins ME, Satterthwaite TD, Ruparel K, Bilker WB, Moore TM, Savitt AP, Hakonarson H, Gur RE. Neurocognitive growth charting in psychosis spectrum youths. JAMA Psychiatry. 2014;71:366–374. doi: 10.1001/jamapsychiatry.2013.4190. [DOI] [PubMed] [Google Scholar]
  • 52.Reichenberg A, Caspi A, Harrington H, Houts R, Keefe RS, Murray RM, Poulton R, Moffitt TE. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am J Psychiatry. 2010;167:160–169. doi: 10.1176/appi.ajp.2009.09040574. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplement 1
NIHMS796764-supplement-Supplement_1.docx (59.9KB, docx)
Supplement 2
NIHMS796764-supplement-Supplement_2.tif (1.3MB, tif)
Supplement 3
NIHMS796764-supplement-Supplement_3.tif (1.6MB, tif)

RESOURCES